MeetingsPremium
MP Journal of Medical Research
Journal of poster communications · ISSN 3144-8402 (Online)
Vol. 1 · 2026-0004
OPEN ACCESS

TYPE
Poster communication

SPECIALTY
Oncology

PRESENTED AT
Journée scientifique de l'APIRR, Rabat, 2–4 September 2026

PUBLISHED
30 September 2026

DOI
10.5281/zenodo.23067714

CORRESPONDENCE
Dr Meryem Chennaq

KEYWORDS
breast cancer · targeted therapy · monoclonal antibodies · small molecules · HER2 · VEGF · CDK 4/6 · PARP · PI3K/AKT/mTOR · ADC

LICENSE
CC BY 4.0. © The authors.

POSTER COMMUNICATION · ONCOLOGY

Targeted therapy in Oncology: breast cancer

Dr Meryem Chennaq[1,2,3]*, Ismail Naffi[1,2], Safaa El Medkouri[1,2,3], Pr Yahia Cherrah[1]

[1] Faculty of Medicine and Pharmacy, Mohammed V University in Rabat
[2] Ibn Sina University Hospital Center
[3] National Institute of Oncology, Ibn Sina University Hospital
* Corresponding author: Dr Meryem Chennaq

English version of a poster presented in French.

KEY MESSAGES

1. Les anticorps monoclonaux ciblant HER2 et VEGF sont essentiels dans le traitement du cancer du sein métastatique.
2. Les petites molécules ciblent des voies spécifiques comme CDK 4/6, PARP et PI3K/AKT/mTOR pour inhiber la progression tumorale.
3. Les thérapies conjuguées (ADC) permettent de délivrer des agents cytotoxiques directement à l'intérieur des cellules cancéreuses.

ABSTRACT

Introduction. Breast cancer is the most common cancer worldwide, affecting more than 2.3 million women globally.

Materials and methods. This poster presents a literature review on the different pharmacological mechanisms of targeted therapies used in breast cancer.

Results. Targeted therapies are classified into several categories: monoclonal antibodies (targeting HER2, VEGF), small molecules (targeting CDK 4/6, PARP, PI3K/AKT/mTOR pathway), and conjugated therapies (ADC: Antibody-drug Conjugates). Each category includes examples of drugs and their specific modes of action.

Conclusion. Targeted therapies represent a major advancement in the treatment of breast cancer, especially for patients with aggressive forms such as HER2-positive cancer.

Online record, HD poster
journal.meetingspremium.com/p/2026-0004

KEY FIGURE




Schéma illustrant les mécanismes d'action des thérapies ciblées sur les cellules cancéreuses du sein.

CITE THIS PUBLICATION

Chennaq M, Naffi I, El Medkouri S, Cherrah Y. Targeted therapy in Oncology: breast cancer [Poster]. MP J Med Res. 2026;1:2026-0004. doi:10.5281/zenodo.23067714

Vancouver format · APA, BibTeX and RIS on the online record

Original poster in high definition on the online record.

SOURCE

Presented at Journée scientifique de l'APIRR, Rabat, 2–4 September 2026. Republished with the agreement of the authors.

PROCESS

Record checked by the editorial team, approved by the corresponding author, then reviewed by the journal's editorial board.

INDEPENDENCE

Partners and advertisers take no part in scientific selection.

© The authors. Open access publication under the Creative Commons Attribution 4.0 International (CC BY 4.0) — https://creativecommons.org/licenses/by/4.0/ license. Published by MeetingsPremium LLC, 75 East 3rd Street, Sheridan, WY 82801, United States.